drugset / Trial / NCT00151125
Phase II Study of IL-11 (Neumega) in Von Willebrand Disease
Phase 2
Completed
12 enrolled
University of Pittsburgh
University of North Carolina · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is testing the use of rhIL-11 (recombinant interleukin 11, Neumega) in individuals with Von Willebrand disease. The purpose is to evaluate: 1. if rhIL-11 corrects VWF (Von Willebrand Factor) levels to normal 2. if rhIL-11 and DDAVP together will boost VWF levels even higher 3. the onset, peak, and duration of rhIL-11 effect 4. if rhIL-11 is safe in individuals with Von Willebrand Disease
Timeline
- Start
- 2004-07
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interleukin-11 | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |
| Subject | Interleukin-11 | Protein / enzyme biologic | 25 ug/kg | Subcutaneous |
| Subject | Interleukin-11 | Protein / enzyme biologic | 50 ug/kg | Subcutaneous |